Business Context and Reporting Period
This Form 8-K is filed by Cerecor Inc. (noting a discrepancy with the request metadata which listed Avalo Therapeutics, Inc.) on September 6, 2016. The report discloses the completion of patient enrollment for a Phase 2 clinical trial of the company's investigational drug, CERC-501, intended for smoking cessation.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a clinical development milestone and does not contain financial statements or quantitative financial data.
Material Changes
The material event reported is the completion of patient enrollment in the Phase 2 clinical trial titled "A Randomized, Double-Blind, Placebo-Controlled, Cross-over Design Study of CERC-501 in a Human Laboratory Model of Smoking Behavior." The primary objective is to evaluate CERC-501's effect on tobacco withdrawal symptoms and smoking behaviors compared to a placebo.
Guidance, Outlook, and Risks
- Outlook: The company expects to report top-line data from this trial in December 2016.
- Regulatory Disclosure: The information provided is furnished under Regulation FD and is not deemed "filed" for purposes of Section 18 of the Exchange Act, nor is it incorporated by reference into other filings except as expressly stated.
- Risks: No specific risks or contingencies are detailed in this text beyond the inherent uncertainty of clinical trial outcomes.
Investor Verification Checklist
- Verify the registrant name is Cerecor Inc., not Avalo Therapeutics, Inc.
- Monitor the expected release of top-line data in December 2016.
- Review the attached press release (Exhibit 99.1) for detailed study parameters.
- Check subsequent filings for financial updates, as none are included in this 8-K.